Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation

摘要

Against the background of statistically significant and clinically meaningful reductions in clinical restenosis with drug-eluting coronary stents (DES), the persistence of adverse events with first- and second-generation permanent polymer-based DES informs the opportunity for iterative improvement [1-3]. Albeit infrequent, the largely unpredictable observations of acquired stent malapposition, stent thrombosis, progression of neointimal growth or incomplete healing have been demonstrated to be related to patient and lesion complexity, in addition to drug and polymer biocompatibility [4-6].